{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009438","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.216265+00:00","generated_at":"2026-06-05T00:38:13.446686+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAffinity closes $2.5M direct offering of 1.6M shares and 1.6M warrants at $1.5625/unit","bullets":["Offering includes 1.6M shares (registered direct) and 1.6M common warrants (private placement) at combined $1.5625/share.","Warrants exercisable at $1.64 per share, subject to shareholder approval, expiring five years after approval date.","Gross proceeds ~$2.5M; net proceeds for working capital and general corporate purposes.","IPO warrant exercise price reduced to $3.0625 upon issuance of new shares and warrants.","WallachBeth Capital acted as sole placement agent; closing occurred March 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009438","json":"https://secwatch.observer/filing/0001493152-24-009438.json","markdown":"https://secwatch.observer/filing/0001493152-24-009438.md","text":"https://secwatch.observer/filing/0001493152-24-009438.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/0001493152-24-009438-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:38:13.446686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2f48ae9bfcbaffbbfd4653ad51852b77fe83e71","claim":"bioAffinity Technologies, Inc. entered into Securities Purchase Agreement with four institutional investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2024-03-06).","evidence_excerpt":"On March 6, 2024, bioAffinity Technologies, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with four institutional investors (the \"Purchasers\"), pursuant to which the Company will issue to the Purchasers, (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock (the \"Shares\"), par value $0.007 per share (\"Common Stock\") and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the \"Common Warrants\") with an exercise price of $1.64.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315224009438/0001493152-24-009438-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"four institutional investors"},{"label":"Value","value":"aggregate gross proceeds of approximately $2.5 million"},{"label":"Effective","value":"2024-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}